StockWatch
·

MYRIAD GENETICS INC Q2 FY26 Results

MYGNQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue190.704.8%10.5%
Total Income190.704.8%10.5%
Expenditure229.600.7%57.7%
PBT-42.6024.9%87.1%
Net Profit-43.2026.7%86.9%
OPM-20.40%5.08pp
NPM-22.65%5.64pp
EPS-0.4627.8%87.1%
View full financials

Myriad Genetics Reports Q2 2026 Financial Results

31 Jul 2026 · 31 Jul, 1:44 am

Summary

Myriad Genetics reported second quarter 2026 revenue of $190.7 million, an 11% decrease year-over-year, driven by lower volumes and average revenue per test. The company experienced an operating loss of $38.9 million and a decrease in gross margin to 66.6%. Despite these challenges, the Cancer Care Continuum business showed positive test volume growth. Management has revised full-year 2026 revenue guidance to a range of $770 to $790 million and is implementing new initiatives focused on efficiency and scalability.

Key Highlights

  1. 1

    Second quarter 2026 revenue was $190.7 million, an 11% decrease year-over-year, attributed to a 1% decline in volume and a 9% decrease in average revenue per test.

  2. 2

    The Cancer Care Continuum business saw test volume growth of 6% year-over-year in the second quarter, with notable launches and expansions.

  3. 3

    Second quarter 2026 gross margin was 66.6%, a decrease of 460 basis points from the prior year's second quarter.

  4. 4

    Operating loss in the second quarter of 2026 was $38.9 million.

  5. 5

    Myriad Genetics revised its 2026 financial guidance, lowering the revenue range to $770 - $790 million.

  6. 6

    Second quarter 2026 cash flow used in operations was $8.3 million, resulting in adjusted free cash flow of $(10.9) million.

Management Comments

S

Sam Raha

In the second quarter, we continued to make meaningful progress on the Cancer Care Continuum on a number of fronts, including 6% year-over-year volume growth supported by the ramp up of our expanded sales team, the launch of Prolaris + AI, the expansion of Precise MRD to include colorectal cancer (CRC) and renal cancers, along with the submission of Precise MRD breast to MolDX. During the quarter, we advanced work on a strategic review with the intention to identify initiatives to increase growth, profitability, and liquidity. We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm. We are also doing a rigorous evaluation of our product portfolio to determine the optimal allocation of capital and enhancement of shareholder value. Myriad Genetics' second quarter 2026 performance fell short of our expectations, as solid demand for our Hereditary Cancer and Mental Health tests was offset by volume challenges in Prenatal Health and increased payer friction. Mitigating average revenue per test pressure for hereditary cancer testing from this increased payer friction is a top priority, and we are executing a comprehensive action plan. The combination of these developments and the first full quarter of increased costs associated with our expanded commercial team yielded pressure on our bottom line in the quarter. While we are revising our full-year 2026 financial guidance due to lower Prenatal Health test volumes and more conservative assumptions regarding average revenue per test, we remain optimistic about our 2027 financial profile as we execute on multiple initiatives.

Informational and educational content only. Not investment advice.